Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is It Too Late to Buy Intellia Therapeutics?

TheMotleyFool

0 0

Healthcare is undergoing a genomics revolution, and Intellia Therapeutics (NASDAQ: NTLA) is leading the way. Founded by Jennifer Doudna, who won the 2020 Nobel Prize in Chemistry for her CRISPR-Cas9 genome editing discovery, Intellia shook the world last month.

In a June 26 press conference, Intellia and its partner Regeneron (NASDAQ: REGN) announced "the first-ever clinical data supporting safety and efficacy of in vivo (in the body) CRISPR genome editing in humans." That rather bland scientific statement should actually send a shiver down your spine. It's now possible to use a "one-and-done" procedure to treat and even cure some deadly genetic diseases.

Image Source: Getty Images.

Source Fool.com

Like: 0

NTLA

Share